vs
EXACT SCIENCES CORP（EXAS）与OSI SYSTEMS INC（OSIS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是OSI SYSTEMS INC的1.9倍（$878.4M vs $464.1M），OSI SYSTEMS INC净利率更高（8.3% vs -9.8%，领先18.1%），EXACT SCIENCES CORP同比增速更快（23.1% vs 10.5%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $55.5M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 7.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
OSI系统公司是总部位于美国加利福尼亚州的企业，主营安全检测系统、医疗设备及光电器件三大业务板块，产品涵盖机场安检X光机、金属探测器、医疗监护与麻醉系统等，旗下拥有Spacelabs Healthcare、Rapiscan Systems、OSI Optoelectronics等子公司，全球员工规模约3180人。
EXAS vs OSIS — 直观对比
营收规模更大
EXAS
是对方的1.9倍
$464.1M
营收增速更快
EXAS
高出12.6%
10.5%
净利率更高
OSIS
高出18.1%
-9.8%
自由现金流更多
EXAS
多$64.9M
$55.5M
两年增速更快
EXAS
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $464.1M |
| 净利润 | $-86.0M | $38.7M |
| 毛利率 | 70.1% | 32.7% |
| 营业利润率 | -9.4% | 12.7% |
| 净利率 | -9.8% | 8.3% |
| 营收同比 | 23.1% | 10.5% |
| 净利润同比 | 90.1% | 2.3% |
| 每股收益（稀释后） | $-0.45 | $2.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASOSIS
| Q4 25 | $878.4M | $464.1M | ||
| Q3 25 | $850.7M | $384.6M | ||
| Q2 25 | $811.1M | $505.0M | ||
| Q1 25 | $706.8M | $444.4M | ||
| Q4 24 | $713.4M | $419.8M | ||
| Q3 24 | $708.7M | $344.0M | ||
| Q2 24 | $699.3M | $480.9M | ||
| Q1 24 | $637.5M | $405.4M |
净利润EXASOSIS
| Q4 25 | $-86.0M | $38.7M | ||
| Q3 25 | $-19.6M | $20.6M | ||
| Q2 25 | $-1.2M | $52.7M | ||
| Q1 25 | $-101.2M | $41.1M | ||
| Q4 24 | $-864.6M | $37.8M | ||
| Q3 24 | $-38.2M | $17.9M | ||
| Q2 24 | $-15.8M | $44.7M | ||
| Q1 24 | $-110.2M | $34.0M |
毛利率EXASOSIS
| Q4 25 | 70.1% | 32.7% | ||
| Q3 25 | 68.6% | 32.0% | ||
| Q2 25 | 69.3% | 33.3% | ||
| Q1 25 | 70.8% | 33.8% | ||
| Q4 24 | 69.0% | 35.1% | ||
| Q3 24 | 69.4% | 35.3% | ||
| Q2 24 | 69.8% | 32.1% | ||
| Q1 24 | 70.0% | 33.6% |
营业利润率EXASOSIS
| Q4 25 | -9.4% | 12.7% | ||
| Q3 25 | -3.0% | 8.6% | ||
| Q2 25 | -0.3% | 14.5% | ||
| Q1 25 | -13.6% | 12.7% | ||
| Q4 24 | -122.8% | 13.8% | ||
| Q3 24 | -5.6% | 8.8% | ||
| Q2 24 | -3.8% | 13.1% | ||
| Q1 24 | -16.7% | 12.7% |
净利率EXASOSIS
| Q4 25 | -9.8% | 8.3% | ||
| Q3 25 | -2.3% | 5.3% | ||
| Q2 25 | -0.1% | 10.4% | ||
| Q1 25 | -14.3% | 9.3% | ||
| Q4 24 | -121.2% | 9.0% | ||
| Q3 24 | -5.4% | 5.2% | ||
| Q2 24 | -2.3% | 9.3% | ||
| Q1 24 | -17.3% | 8.4% |
每股收益（稀释后）EXASOSIS
| Q4 25 | $-0.45 | $2.22 | ||
| Q3 25 | $-0.10 | $1.18 | ||
| Q2 25 | $-0.01 | $3.04 | ||
| Q1 25 | $-0.54 | $2.40 | ||
| Q4 24 | $-4.69 | $2.22 | ||
| Q3 24 | $-0.21 | $1.05 | ||
| Q2 24 | $-0.09 | $2.57 | ||
| Q1 24 | $-0.60 | $1.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $336.7M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $2.4B | $845.5M |
| 总资产 | $5.9B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资EXASOSIS
| Q4 25 | $964.7M | $336.7M | ||
| Q3 25 | $1.0B | $124.4M | ||
| Q2 25 | $858.4M | $106.4M | ||
| Q1 25 | $786.2M | $95.8M | ||
| Q4 24 | $1.0B | $101.6M | ||
| Q3 24 | $1.0B | $85.1M | ||
| Q2 24 | $946.8M | $95.4M | ||
| Q1 24 | $652.1M | $101.4M |
总债务EXASOSIS
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $442.2M | ||
| Q2 25 | — | $471.6M | ||
| Q1 25 | — | $473.2M | ||
| Q4 24 | — | $474.8M | ||
| Q3 24 | — | $476.3M | ||
| Q2 24 | — | $137.6M | ||
| Q1 24 | — | — |
股东权益EXASOSIS
| Q4 25 | $2.4B | $845.5M | ||
| Q3 25 | $2.5B | $946.0M | ||
| Q2 25 | $2.5B | $951.1M | ||
| Q1 25 | $2.4B | $879.3M | ||
| Q4 24 | $2.4B | $825.8M | ||
| Q3 24 | $3.2B | $786.5M | ||
| Q2 24 | $3.2B | $863.5M | ||
| Q1 24 | $3.1B | $813.4M |
总资产EXASOSIS
| Q4 25 | $5.9B | $2.5B | ||
| Q3 25 | $5.9B | $2.3B | ||
| Q2 25 | $5.8B | $2.2B | ||
| Q1 25 | $5.7B | $2.1B | ||
| Q4 24 | $5.9B | $2.1B | ||
| Q3 24 | $6.7B | $2.1B | ||
| Q2 24 | $6.7B | $1.9B | ||
| Q1 24 | $6.4B | $1.8B |
负债/权益比EXASOSIS
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.57× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $62.2M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $55.5M |
| 自由现金流率自由现金流/营收 | 13.7% | 12.0% |
| 资本支出强度资本支出/营收 | 3.6% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 1.61× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $137.2M |
8季度趋势，按日历期对齐
经营现金流EXASOSIS
| Q4 25 | $151.7M | $62.2M | ||
| Q3 25 | $219.9M | $17.1M | ||
| Q2 25 | $89.0M | $562.0K | ||
| Q1 25 | $30.8M | $81.6M | ||
| Q4 24 | $47.1M | $52.5M | ||
| Q3 24 | $138.7M | $-37.2M | ||
| Q2 24 | $107.1M | $-29.0M | ||
| Q1 24 | $-82.3M | $-52.1M |
自由现金流EXASOSIS
| Q4 25 | $120.4M | $55.5M | ||
| Q3 25 | $190.0M | $10.1M | ||
| Q2 25 | $46.7M | $-5.6M | ||
| Q1 25 | $-365.0K | $77.1M | ||
| Q4 24 | $10.7M | $47.1M | ||
| Q3 24 | $112.6M | $-44.9M | ||
| Q2 24 | $71.2M | $-37.5M | ||
| Q1 24 | $-120.0M | $-57.0M |
自由现金流率EXASOSIS
| Q4 25 | 13.7% | 12.0% | ||
| Q3 25 | 22.3% | 2.6% | ||
| Q2 25 | 5.8% | -1.1% | ||
| Q1 25 | -0.1% | 17.4% | ||
| Q4 24 | 1.5% | 11.2% | ||
| Q3 24 | 15.9% | -13.0% | ||
| Q2 24 | 10.2% | -7.8% | ||
| Q1 24 | -18.8% | -14.1% |
资本支出强度EXASOSIS
| Q4 25 | 3.6% | 1.4% | ||
| Q3 25 | 3.5% | 1.8% | ||
| Q2 25 | 5.2% | 1.2% | ||
| Q1 25 | 4.4% | 1.0% | ||
| Q4 24 | 5.1% | 1.3% | ||
| Q3 24 | 3.7% | 2.2% | ||
| Q2 24 | 5.1% | 1.8% | ||
| Q1 24 | 5.9% | 1.2% |
现金转化率EXASOSIS
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 1.98× | ||
| Q4 24 | — | 1.39× | ||
| Q3 24 | — | -2.07× | ||
| Q2 24 | — | -0.65× | ||
| Q1 24 | — | -1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
OSIS
| Security Division | $334.7M | 72% |
| Optoelectronics And Manufacturing Division | $92.8M | 20% |
| Healthcare Division | $36.5M | 8% |
